Last reviewed · How we verify
IDO peptide vaccination
At a glance
| Generic name | IDO peptide vaccination |
|---|---|
| Sponsor | Inge Marie Svane |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma (PHASE1, PHASE2)
- IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (PHASE1)
- Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDO peptide vaccination CI brief — competitive landscape report
- IDO peptide vaccination updates RSS · CI watch RSS
- Inge Marie Svane portfolio CI